Immunic, Inc. (NASDAQ:IMUX) Receives $12.25 Consensus PT from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have received an average recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $11.80.

IMUX has been the subject of a number of research reports. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright assumed coverage on shares of Immunic in a report on Monday. They set a “buy” rating and a $10.00 target price for the company. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. B. Riley started coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price on the stock. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Immunic in a report on Monday, September 9th.

Immunic Stock Up 7.3 %

Immunic stock opened at $1.18 on Friday. The stock has a 50-day moving average price of $1.39 and a 200 day moving average price of $1.34. The company has a market capitalization of $106.29 million, a price-to-earnings ratio of -0.96 and a beta of 1.88. Immunic has a 52 week low of $0.97 and a 52 week high of $2.11.

Insider Buying and Selling

In other Immunic news, Director Richard Alan Rudick bought 87,300 shares of Immunic stock in a transaction on Tuesday, November 12th. The shares were bought at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the transaction, the director now directly owns 87,300 shares of the company’s stock, valued at $100,395. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 3.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently bought and sold shares of IMUX. Vanguard Group Inc. boosted its stake in shares of Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares during the period. Janus Henderson Group PLC purchased a new stake in Immunic during the 1st quarter worth about $9,266,000. Ikarian Capital LLC increased its stake in shares of Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares during the period. Jane Street Group LLC lifted its stake in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.